Johnson & Johnson said on Thursday it will discontinue a late-stage study of an experimental E.coli vaccine it was developing in partnership with Sanofi.
The drugmaker said its decision was based on the recommendation of an independent committee that found the vaccine candidate may not be sufficiently effective compared with a placebo in preventing infections caused by a group of bacteria commonly found in the gut.
No safety signals related to the experimental vaccine were identified, J&J said, adding that it was conducting follow-ups for participants currently enrolled in the trial.
The study was testing the safety and efficacy of a single dose of the experimental shot, ExPEC9V, in preventing E.coli disease, including sepsis and blood infections.
Read next
10:53
Ebola
Uganda has launched a trial vaccination program for the Sudan strain of Ebola as confirmed cases rise to three. With no approved vaccine for this strain, the trial aims to protect communities and strengthen outbreak response, according to the WHO.
17:30
The WHO has approved Abbott Laboratories' mpox diagnostic test for emergency use, marking a key step in boosting testing in outbreak-hit countries. The real-time PCR test detects mpox virus DNA from skin swabs, with more tests under review to increase diagnostic availability worldwide.
14:00
Researchers at the University of Oxford are developing OvarianVax, a vaccine aimed at training the immune system to detect early signs of ovarian cancer.
01:40
The FDA has approved AstraZeneca's treatment for use outside of healthcare facilities, but it will still require a prescription.
What is your opinion on this topic?
Leave the first comment